Pfizer battles another Paxlovid lawsuit from Enanta
If you don’t succeed at first, try again – in separate regions. That’s the motto Enanta Pharmaceuticals is following, at …
Post
-
-
Madrigal wins European MASH approval as Novo rivalry looms
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to …
-
FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug
Bristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration (FDA) for izalontamab …
-
PTC’s vatiquinone approval hopes dashed in Friedreich’s Ataxia
The US Food and Drug Administration (FDA) has rejected PTC Therapeutics’ new drug application (NDA) for vatiquinone in Friedreich's Ataxia. This …
-
āshibio licences vantictumab for rare bone disorder
Biotechnology company āshibio has entered an exclusive licencing agreement with Mereo BioPharma for the monoclonal antibody, vantictumab, to treat a …
-
Viking’s stock plummets on obesity pill trial results
Viking Therapeutics’ dual-targeting oral weight loss drug has disappointed investors after it showed lower efficacy than offerings from pharma …
-
Trade-offs abound as big pharma makes direct-to-consumer transition
Novo Nordisk is the latest drugmaker to slash the price of a blockbuster medicine via its online platform amid drug …
-
Accelerating healthcare marketing: How a data-driven strategy can transform lead generation
The pressure is mounting. With increased competition across medtech, pharma, diagnostics, and digital health, cutting through the noise requires more …
-
Data Points to Potential for Patient Centricity in Rare Disease Trial Success
For health policymakers at a national level, rare diseases are those affecting a tiny fraction of the population. Worldwide, however, this …
-
CSL slashes 15% of workforce and offshoots vaccine division
Australia’s largest pharmaceutical company CSL will reduce its headcount by 15% and spin off its vaccine division in response to …
-
Santen and RemeGen sign licence deal for retinal disease injection
Santen Pharmaceutical has signed a licensing agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein designed to …
-
Merck announces EC approval of Ogsiveo for desmoid tumours
The European Commission (EC) has granted marketing authorisation to SpringWorks Therapeutics, a subsidiary of Merck KGaA, for Ogsiveo (nirogacestat) to …
-
Boehringer Ingelheim marks retinal disease push with $327m licensing deal
Boehringer Ingelheim currently does not have any approved therapies for ophthalmic indications, but the company is looking to change that …
-
Accelerating diagnosis and drug development with better managed datasets
Every aspect of science and research is based on data, and across the globe, labs are producing more data than …
-
Novel software solutions can ease transition in an age of clinical supply chain upheaval
The healthcare landscape faces turbulent times. Regulatory pressures, challenges around demand forecasting and an influx of novel therapies are heaping …
